Swiss biotech ImmunOs Therapeutics today announced that Steve Coats has been appointed as chief development officer (CDO).
Mr Coats brings more than 25 years of industry expertise with a focus on antibody drug development that includes scientific excellence coupled with executive-level success, driving strategic initiatives and innovations in drug development. Prior to joining ImmunOs, Mr Coats served as CDO at Auregen Biotherapeutics, managing and leading R&D laboratories to develop innovative cell therapies and building a strong development pipeline.
From 2005 to 2020, he held several leading positions of increasing responsibility at AstraZeneca (LSE: AZN)_and MedImmune, most recently as vice president R&D, global project leader. From 1996 to 2005, he held various research positions of increasing responsibility at Amgen (Nasdaq: AMGN), where he focused on identifying the right targets and mechanistic areas in cancer for drug development of both small molecule and biologic-based therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze